Financial Performance - Consolidated revenue for Q4 2024 was $100 million, an increase of 16.9% compared to Q4 2023[8] - Consolidated revenue for the year ended December 31, 2024 was $393 million, an increase of 21.3% compared to the prior year[13] - Total operating revenue for Q4 2024 was $100,267,000, an increase of 16.8% compared to $85,788,000 in Q4 2023[43] - Total operating revenue for the year ended December 31, 2024 was $393,412,000, a 21.4% increase from $324,239,000 in 2023[43] - For the fiscal year 2025, the company expects revenue between $460 million and $480 million[7] Cash Flow and Assets - Cash flow from operations in Q4 2024 was approximately $4.2 million, driven by disciplined working capital management[5] - Cash and cash equivalents increased to $49,669 in 2024 from $33,488 in 2023, marking a growth of 48.4%[42] - Cash and cash equivalents at the end of Q4 2024 were $49,669,000, compared to $33,488,000 at the end of Q4 2023, reflecting an increase of 48.3%[44] - The company reported a net cash provided by operating activities of $4,186,000 in Q4 2024, compared to cash used of $3,882,000 in Q4 2023[44] Expenses and Losses - Selling, general, and administrative expenses decreased 12% in Q4 2024 compared to the prior year period, totaling $25 million[5] - Adjusted EBITDA for Q4 2024 was $(7.8) million, a decrease of $1.6 million compared to Q4 2023[12] - Net loss for Q4 2024 was $13.2 million, a decrease of $5.6 million compared to Q4 2023[12] - Net loss for the three months ended December 31, 2024, was $13,182, a decrease of 29.7% from a net loss of $18,754 in 2023[29] - Adjusted EBITDA for the year ended December 31, 2024, was $(35,688), representing a decline of 38.3% compared to $(25,805) in 2023[35] - Operating expenses totaled $112,196,000 in Q4 2024, up from $101,076,000 in Q4 2023, an increase of 11.1%[43] Revenue Sources - Dispensary revenue increased 72.4% compared to Q4 2023, attributed to an increase in filled prescriptions and average revenue per prescription[9] - Dispensary revenue increased significantly to $47,587,000 in Q4 2024 from $27,607,000 in Q4 2023, representing a growth of 72.2%[43] - Patient services revenue decreased to $50,217,000 in Q4 2024 from $56,171,000 in Q4 2023, a decline of 10.4%[43] Assets and Liabilities - Total current assets decreased to $112,418 as of December 31, 2024, down from $143,493 in 2023, reflecting a reduction of 21.6%[42] - The total liabilities increased to $169,128 in 2024 from $152,215 in 2023, an increase of 11.1%[42] - The accumulated deficit grew to $(210,813) in 2024 from $(146,150) in 2023, indicating a deterioration of 44.2%[42] Operational Growth - The number of clinics increased to 86 in 2024 from 83 in 2023, indicating a growth of 3.6%[41] - Lives under value-based contracts rose to 1.9 million in 2024, up from 1.8 million in 2023, representing a growth of 5.6%[41] - The company launched six new contracts in Q3 and Q4 2024, covering over 250,000 lives, with value-based patient services increasing sequentially by over 15%[5] Shareholder Information - The weighted-average number of shares outstanding increased to 75,655,231 in Q4 2024 from 73,469,101 in Q4 2023[43] - Share-based compensation decreased by 36.4% to $11,152 in 2024 from $17,548 in 2023[35] Impairment Charges - The company incurred goodwill impairment charges of $16,867,000 in 2023, which were not present in 2024[43]

Core Insights - The Oncology Institute, Inc. (TOI) reported a consolidated revenue of $100 million for Q4 2024, marking a 16.9% increase compared to Q4 2023, driven primarily by dispensary revenue growth [9][14] - The company achieved a net loss of $13.2 million in Q4 2024, an improvement from a net loss of $18.8 million in the same quarter of the previous year [13][18] - For the fiscal year 2025, TOI projects revenue between $460 million and $480 million, with gross profit expected to be between $73 million and $82 million [6] Recent Operational Highlights - TOI successfully reduced cash burn and generated positive cash flow from operations for the second consecutive quarter, amounting to approximately $4.2 million in Q4 2024 [4][7] - The company launched six new contracts in Q3 and Q4 2024, covering over 250,000 lives, contributing to a sequential increase of over 15% in value-based patient services [7][10] - A new agreement with the primary drug supplier improved discounts, optimizing cost positioning for revenue growth targets [7] Financial Performance - Q4 2024 gross profit was $15 million, a 1.8% increase from Q4 2023, while selling, general, and administrative expenses decreased by 12% year-over-year [11][12] - The total revenue for the year ended December 31, 2024, was $393 million, reflecting a 21.3% increase compared to the previous year [14] - Adjusted EBITDA for Q4 2024 was $(7.8) million, a decrease from $(6.3) million in Q4 2023, primarily due to changes in share-based compensation and fair value of derivative liabilities [13][19] Guidance and Outlook - The company anticipates Adjusted EBITDA of approximately $(5) to $(6) million for Q1 2025, influenced by seasonal factors such as drug price increases and lower encounter volumes [8] - TOI's outlook for 2025 assumes a largely reopened global market, with potential impacts from any reimplementation of restrictive measures [8] Key Business Metrics - As of December 31, 2024, TOI operated 86 clinics and served approximately 1.9 million patients under value-based contracts [41] - The company reported cash, cash equivalents, and investments totaling $50 million as of December 31, 2024 [7]

Core Viewpoint - The Oncology Institute, Inc. (TOI) has announced a private placement expected to generate approximately $16.5 million in gross proceeds, aimed at supporting organic growth and working capital needs [1][5]. Group 1: Private Placement Details - The private placement involves accredited investors and includes participation from existing investors and members of the management team and Board of Directors [1]. - Each unit in the private placement consists of two shares of common stock (or pre-funded warrants) and common warrants to purchase one share of common stock at a price of $2.2084 per unit [2]. - The pre-funded warrants will have an exercise price of $0.0001 per share, while the common warrants will have an exercise price of $1.1980 per share [2]. Group 2: Exchange Agreement - Deerfield Management Company has agreed to exchange approximately $4.1 million of the Company's senior secured convertible notes for 37,232.83 shares of common-equivalent preferred stock and warrants to purchase 1,861,642 shares of common stock at the same prices as the private placement [4]. Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to support organic growth and working capital needs [5]. Group 4: Company Overview - Founded in 2007, TOI is one of the largest value-based community oncology groups in the U.S., providing specialized cancer care to over 1.8 million patients [8]. - The organization employs over 120 clinicians and has more than 700 team members across over 70 clinic locations [8].

Core Viewpoint - The Oncology Institute, Inc. (TOI) will announce its fourth quarter and full year 2024 financial results on March 25, 2025, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - TOI will release its financial results after market close on March 25, 2025 [1]. - A conference call will take place on the same day at 5:00 p.m. Eastern Time [1]. Group 2: Conference Call Access - The conference call can be accessed by phone at 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2]. - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13750791 [2]. - The replay will be available until April 1, 2025 [2]. Group 3: Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4]. - TOI provides advanced cancer care services, including clinical trials and transfusions, aiming to improve oncology care delivery [4].

Core Insights - Topicus.com Inc. reported strong financial results for Q4 and the full year 2024, with total revenue reaching €364.9 million for the quarter and €1,294.9 million for the year, marking increases of 18% and 15% respectively compared to 2023 [5][8] - The company's net income for Q4 2024 was €56.2 million, a 32% increase from €42.5 million in Q4 2023, while the annual net income rose to €149.5 million, up 30% from €115.4 million in 2023 [6][8] - Cash flows from operations (CFO) also saw significant growth, increasing by 28% to €79.6 million in Q4 and by 41% to €347.6 million for the full year [7][8] Financial Performance - Total revenue for Q4 2024 was €364.9 million, up from €309.7 million in Q4 2023, driven by acquisitions and organic growth of 5% [5][8] - For the full year 2024, total revenues were €1,294.9 million, compared to €1,125.0 million in 2023, with organic growth also at 5% [5][8] - Net income for Q4 2024 was €56.2 million, translating to €0.40 per share, compared to €42.5 million (€0.31 per share) in Q4 2023 [6][8] - Annual net income increased to €149.5 million (€1.11 per share) from €115.4 million (€0.88 per share) in 2023 [6][8] Cash Flow and Acquisitions - CFO for Q4 2024 increased to €79.6 million from €62.4 million in Q4 2023, representing a 28% growth [7][8] - For the full year, CFO rose to €347.6 million from €246.6 million, a 41% increase [7][8] - Free cash flow available to shareholders (FCFA2S) for Q4 2024 was €36.6 million, up 27% from €28.9 million in Q4 2023, and for the full year, it increased to €177.4 million from €123.4 million, a 44% rise [9][8] - The company completed acquisitions for a total cash consideration of €153.4 million in 2024, including holdbacks and contingent considerations [8] Balance Sheet Highlights - As of December 31, 2024, total assets were €1,535.9 million, up from €1,432.8 million in 2023 [15][16] - Current assets included cash of €206.2 million and accounts receivable of €142.8 million [15] - Total liabilities increased to €1,004.5 million from €840.3 million in 2023, with current liabilities including a revolving credit facility of €225.7 million [16] Shareholder Returns - The company paid dividends totaling €127.6 million to shareholders in 2024 [26] - Retained earnings as of December 31, 2024, were €266.3 million, down from €297.4 million in 2023 [21][23]

Core Viewpoint - The Oncology Institute, Inc. (TOI) has amended its facility agreement with Deerfield Management Company, allowing for greater financial flexibility and a partial paydown of senior secured convertible notes [1][2][3]. Financial Agreement - Deerfield has waived certain restrictions on TOI's ability to offer and sell equity and removed the minimum cash covenant of $40 million [2]. - TOI has paid down approximately $20 million of the senior secured convertible notes along with accrued and unpaid interest [2]. Growth Initiatives - TOI has signed three new capitation agreements year to date, adding approximately 80,000 lives across California, Nevada, and Florida [3]. - The total lives under value-based agreements in Florida now exceed 200,000, with over 50,000 under Medicare Advantage [3]. Company Overview - Founded in 2007, TOI is a leading provider of value-based cancer care in the community setting, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4].

Group 1 - Topicus.com Inc. plans to release its fourth quarter results on February 26, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on the release date [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus specializes in acquiring, managing, and building vertical market software businesses [2]

Group 1 - Topicus.com Inc. has announced the acquisition of 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share from Cyfrowy Polsat S.A. [1] - Topicus.com Inc.'s subsidiaries Yukon Niebieski Kapital B.V. and TSS Europe B.V. have signed a shareholders' agreement with the Adam Góral Family Foundation to govern their cooperation regarding their shareholdings in Asseco Poland S.A. [1] - The shareholders' agreement will take effect upon the completion of Yukon's acquisition of 12,318,863 treasury shares from Asseco Poland S.A., representing 14.84% of the company's share capital, also at a price of 85 PLN per share [1] Group 2 - Asseco Group operates in the information technology sector and has a presence in 62 countries, offering proprietary IT solutions across various economic sectors [3] - The Adam Góral Family Foundation, established by the CEO of Asseco Poland, operates under the Polish Family Foundation Act and is registered in Rzeszów, Poland [4] - Topicus.com Inc. is a leading provider of vertical market software in Europe, focusing on acquiring and managing software companies that provide specialized solutions for public and private sector clients [5]

Group 1 - Topicus.com Inc. announced the acquisition of 8,300,029 shares in Asseco Poland S.A. from Cyfrowy Polsat S.A., representing approximately 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share [1] - Asseco Group operates in 62 countries and is engaged in information technology, offering comprehensive IT solutions for all sectors of the economy [2] - Topicus.com Inc. is a pan-European provider of vertical market software and platforms, focusing on long-term growth potential in various European markets [3] Group 2 - Cyfrowy Polsat S.A. is a leading media and telecom group in Poland, providing digital pay-TV, telephony, broadband internet, and operating in renewable energy [4]

Core Insights - Florida Blue has launched a new oncology care model aimed at improving access to high-quality cancer care for its myBlue members, developed in collaboration with Sanitas Medical Centers and The Oncology Institute [1][4] - The program focuses on personalized, evidence-based treatment plans and emphasizes collaboration between oncologists and primary care providers to enhance patient outcomes and overall health [3][4] Company Overview - Florida Blue is the leading health insurer in Florida, serving over six million members across all 67 counties and has been in operation for more than 80 years [6] - The Oncology Institute is a prominent value-based oncology group in the U.S., providing high-quality cancer care at 14 locations in Central and South Florida [2][12] - Sanitas Medical Centers offers comprehensive primary care to nearly half a million Florida Blue members through 60 locations [2] Program Details - The new oncology care model connects myBlue members diagnosed with cancer to their own TOI oncology team, ensuring personalized treatment plans and support from primary care providers [3] - The program aims to facilitate seamless communication and coordination among healthcare providers, patients, and their families, enhancing the overall care experience [3][4] Enrollment Information - Individuals not currently enrolled in myBlue can sign up during the Marketplace open enrollment period, which ends on January 15, or at any time if they qualify for special enrollment [5]